Memorial Sloan Kettering Cancer Center (MSKCC) is a free-standing institution dedicated to the control of cancer through in-patient and out-patient care, clinical and research training programs, and a broad spectrum of research activities. MSKCC's research programs are grouped into three categories: Basic Research (Cellular Structure, Cell Signaling and Regulation, Developmental Biology, Genomic Integrity, and Molecular Structure); Bridge Disciplines (Cancer Biology and Experimental Pathology, Experimental Therapeutics, Immunology and Transplantation, and Imaging and Radiation Science), and Patient-Oriented Research (Clinical Research and Prevention, Control, and Population Research). The programs are designed to optimize the use of a large patient population and an extensive, multi-disciplinary staff of clinical and laboratory-based investigators, and to encourage the application of discoveries in the basic sciences in a way that advances the prevention, detection, diagnosis, and treatment of many forms of cancer. Scientific work in the eleven research programs depends on services provided by 36 core facilities, 20 of which will receive funding from the Cancer Center Support Grant (CCSG). During the next five years, under recently recruited leadership, MSKCC will enlarge its clinical and research facilities and its research and training programs; therefore, an expanded budget is requested to establish the laboratories of new investigators in several fields of inquire and to develop additional core facilities.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-39
Application #
6708086
Study Section
Subcommittee G - Education (NCI)
Program Officer
Shafik, Hasnaa
Project Start
1977-01-01
Project End
2007-12-31
Budget Start
2004-01-01
Budget End
2004-12-31
Support Year
39
Fiscal Year
2004
Total Cost
$9,841,966
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Pulitzer, Melissa; Geller, Shamir; Kumar, Erica et al. (2018) T-cell receptor-? expression and ??+ T-cell infiltrates in primary cutaneous ?? T-cell lymphoma and other cutaneous T-cell lymphoproliferative disorders. Histopathology 73:653-662
Geller, Shamir; Dickson, Mark A; Busam, Klaus J et al. (2018) Kaposi's Sarcoma After Autologous Stem-Cell Transplantation and Rituximab Treatment. J Oncol Pract 14:565-568
Brand, Christian; Sadique, Ahmad; Houghton, Jacob L et al. (2018) Leveraging PET to image folate receptor ? therapy of an antibody-drug conjugate. EJNMMI Res 8:87
Jiang, Jue; Hu, Yu-Chi; Tyagi, Neelam et al. (2018) Tumor-aware, Adversarial Domain Adaptation from CT to MRI for Lung Cancer Segmentation. Med Image Comput Comput Assist Interv 11071:777-785
Cifani, Paolo; Dhabaria, Avantika; Chen, Zining et al. (2018) ProteomeGenerator: A Framework for Comprehensive Proteomics Based on de Novo Transcriptome Assembly and High-Accuracy Peptide Mass Spectral Matching. J Proteome Res 17:3681-3692
Ito, Kimiteru; Schöder, Heiko; Teng, Rebecca et al. (2018) Prognostic value of baseline metabolic tumor volume measured on 18F-fluorodeoxyglucose positron emission tomography/computed tomography in melanoma patients treated with ipilimumab therapy. Eur J Nucl Med Mol Imaging :
Shah, Gunjan L; Scordo, Michael; Kosuri, Satyajit et al. (2018) Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 24:142-149
Abraham, Ann; Zhang, Alysandra J; Ahn, Rosa et al. (2018) Media Content Analysis of Marijuana's Health Effects in News Coverage. J Gen Intern Med 33:1438-1440
Maiga, Amelia W; Deppen, Stephen A; Mercaldo, Sarah Fletcher et al. (2018) Assessment of Fluorodeoxyglucose F18-Labeled Positron Emission Tomography for Diagnosis of High-Risk Lung Nodules. JAMA Surg 153:329-334
Raj, Nitya; Reidy-Lagunes, Diane (2018) The Role of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography in Well-Differentiated Neuroendocrine Tumors: A Case-Based Approach Illustrates Potential Benefits and Challenges. Pancreas 47:1-5

Showing the most recent 10 out of 8799 publications